AEye, Inc. - Warrant (LIDRW)

On our options desk, LIDRW has essentially flatlined down to penny levels around $0.01 to $0.06 with support and resistance completely pinned. With Nasdaq officially executing a Form 25-NSE voluntary withdrawal under Section 12(b) to delist and remove the warrant securities from registration, any traditional leveraged upside thesis for derivative holders is effectively dead. Even though the underlying common stock LIDR is trading around $1.28 and posting triple-digit percentage revenue growth with new verticals like Alive3D and validation on NVIDIA DRIVE AGX Thor, the warrants offer virtually no price cushion or viable recovery trajectory.

From a risk management standpoint, holding LIDRW right now is a masterclass in asymmetric downside with zero structural liquidity left. The SEC filings confirm the Nasdaq delisting is fully underway. While AEye's fundamental metrics show some bright spots—such as Q2 2026 revenue surging nine-fold year-over-year to $202 thousand and first-half revenue eclipsing full-year 2025 totals—the company continues to burn substantial cash with a Q2 net loss of $10.0 million and negative gross margins. The cash position of $71.5 million gives the operating entity runway, but the warrant vehicle itself provides no protection against these fundamental equity headwinds.

As a quant monitoring micro-cap structured assets, the technical setup on LIDRW is completely broken. Convergence at absolute penny levels with persistent selling pressure shows that market makers and retail participants are abandoning the instrument entirely in response to the exchange delisting notices. Analysts looking at AEye's modular lidar platform, Tier 1 partnership challenges, and reliance on single-source components need to separate the underlying common equity dynamics from the warrant death spiral. Do not treat LIDRW as a viable leveraged proxy for LIDR given the regulatory removal from Nasdaq.

Looking at the broader market chatter across financial forums, sentiment on LIDR common stock remains cautious due to persistent commercialization hurdles and supply chain constraints, despite defense sector purchase orders and automotive ecosystem wins. However, the conversation around LIDRW is non-existent outside of distress liquidations. When a warrant class gets stripped of its major exchange listing via Form 25, the clearing and execution friction alone makes secondary market participation untenable for institutional mandates.

As a hedge fund portfolio manager evaluating small-cap tech washouts, the divergence between AEye's operational progress—like the third consecutive purchase order from their lead defense customer and the Alive3D sports analytics deal—and the absolute destruction of their warrant class highlights the perils of derivative instruments in distressed equities. The Form 25-NSE filing is the final nail in the coffin for LIDRW. We are advising all accounts to completely write off any residual value in the warrant line item while selectively reviewing the common stock's path toward commercial adoption.